Chemed Corp (CHE) Q2 2024 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2024. Chemed Corporation operates through two primary segments: VITAS Healthcare (hospice care) and Roto-Rooter (plumbing, drain cleaning, and water restoration). The company reported strong growth in its VITAS segment, offset by a decline in Roto-Rooter revenues.
Key Financial Metrics
| Metric | Q2 2024 | Q2 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Service Revenues | $595.9M | $553.8M | $1,185.1M | $1,114.0M |
| Net Income | $70.9M | $53.4M | $135.9M | $107.5M |
| Diluted EPS | $4.65 | $3.51 | $8.89 | $7.09 |
| Adjusted EBITDA | $119.9M | $96.3M | $234.5M | $196.4M |
| Operating Cash Flow (YTD) | $162.1M | $192.8M | - | - |
| Cash & Equivalents | $222.9M | $264.0M (Dec '23) | - | - |
| Debt | $0 (Term Loan Paid) | $0 | - | - |
| Available Credit | $404.8M | - | - | - |
Note: The company paid off its $100M term loan in April 2023. As of June 30, 2024, there is no outstanding long-term debt, only a $450M revolving credit facility with $404.8M available.
Material Changes vs. Prior Period
- Revenue Growth: Consolidated revenue increased 7.6% in Q2 and 6.4% YTD. This was driven by a 16.7% increase in VITAS revenue (due to a 14.4% rise in days-of-care and a 2.5% Medicare rate increase) offset by a 5.0% decline in Roto-Rooter revenue (driven by lower job counts across all service lines).
- Profitability: Net income rose 32.8% in Q2. VITAS after-tax earnings margin improved to 13.1% from 8.1% in the prior year, aided by the expiration of the 2023 healthcare worker retention bonus program. Roto-Rooter net income declined due to revenue contraction.
- Acquisitions: On April 17, 2024, VITAS acquired Covenant Care for $85.0M in cash, adding $77.1M to goodwill. This acquisition is expected to contribute $30M-$32M to full-year VITAS revenue.
- Cash Flow: Operating cash flow decreased $30.7M YTD compared to the prior year, primarily due to timing of payments, a decrease in accounts payable, and litigation settlement payments.
Guidance, Outlook, and Risks
- 2024 Guidance:
- VITAS: Revenue estimated to increase 16.0%–17.0% (pre-Medicare Cap). Adjusted EBITDA margin estimated at 19.0%–19.5% (pre-Medicare Cap). Estimated Medicare Cap billing limitations of $8.5M for 2024.
- Roto-Rooter: Revenue forecasted to decline 4.0%–5.0%. Adjusted EBITDA margin expected to be 26.5%–27.0%.
- Full-Year EPS: Adjusted diluted EPS estimated at $23.55–$23.80 (up from previous guidance of $23.30–$23.70).
- Risks & Contingencies:
- Regulatory Audit: VITAS is appealing a Medicare audit recommendation regarding inpatient and continuous care claims from 2017–2019. The company has deposited $50.3M under "Immediate Recoupment" to preserve appeal rights, with $3.34M refunded to date. The outcome remains uncertain.
- Concentration Risk: Approximately 85% of consolidated accounts receivable are from Medicare, Medicaid, and managed Medicaid programs.
- Market Risk: Interest rate risk exists on the variable-rate revolving credit facility, though no variable debt was outstanding as of June 30, 2024.
Investor Verification Checklist
- Medicare Cap Impact: Verify the actual impact of the estimated $8.5M Medicare Cap billing limitation on VITAS's full-year revenue and margins.
- Roto-Rooter Job Counts: Monitor the trend in job counts for Roto-Rooter's core services (drain cleaning, plumbing) to assess if the 5% revenue decline is structural or cyclical.
- Regulatory Resolution: Track the status of the $50.3M Medicare audit appeal and potential additional repayment obligations.
- Capital Allocation: Review the pace of share repurchases ($88.1M YTD) and the remaining $225.9M authorization under the current program.
- Acquisition Integration: Assess the revenue and EBITDA contribution from the Covenant Care acquisition against the projected $30M–$32M revenue and $8M–$8.5M EBITDA targets.